Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Rituximab beats the odds in ITP? a 5-year national showdown against TPO-ras

View Full Paper
Ask AI
Bookmark
Share

Authors

BZBugra ZenginHamilton Medical CenterKOKinan ObeidatThe University of Texas Medical Branch at GalvestonLDLisa A. DuhaimeHamilton Medical Center

Discussion

Loading...

Member takes

Implication

Retrospective cohort study demonstrates rituximab improves survival and platelet control in ITP, suggesting a favorable second-line treatment option.

Key Points

  • This study aims to compare the clinical outcomes of rituximab and thrombopoietin receptor agonists in treating immune thrombocytopenia over five years.
  • Retrospective cohort study using TriNetX US Collaborative Network data from 68 healthcare organizations.
  • Identified adult patients diagnosed with ITP, stratified into rituximab and TPO-RA groups.
  • Performed propensity score matching to balance demographic and clinical covariates.
  • Rituximab-treated patients had a 5-year survival rate of 76.8% compared to 69.7% for TPO-RA.
  • Fewer rituximab patients experienced critically low platelet counts (<10,000/μL) than those on TPO-RAs.
  • Higher hospitalization rates were observed in the rituximab group (59.6% vs. 55.1%).

Cite This Study

Zengin et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d315https://doi.org/10.1182/blood-2025-735
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of rituximab as treatment for immune thrombocytopenic purpura in patients who have failed steroids or IVIG: A retrospective study in a community practice.2024
  2. 2Short-term outcomes of rituximab versus thrombopoietin receptor agonists in Myelodysplastic Syndromes: A 90-day propensity-matched analysis using real-world data2025
  3. 3Efficacy of thrombopoietin receptor agonists versus rituximab in non‐responsive immune thrombocytopenia—A single centre retrospective analysis2024 · 1 citations
  4. 4The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial2025
  5. 5A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP2015 · 114 citations